Avalyn Pharma
Signal active
Organization
Contact Information
Overview
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics.
Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
About
Industries
Biotechnology, Pharmaceutical, Medical, Biopharma
Founded
2011
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Avalyn Pharma headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $13.1B in funding across 48 round(s). With a team of 11-50 employees, Avalyn Pharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Avalyn Pharma, raised $175.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
14
Lead Investors
0
Total Funding Amount
$272.5M
Details
3
Avalyn Pharma has raised a total of $272.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2017 | Early Stage Venture | 62.0M | ||
| 2020 | Early Stage Venture | 35.5M | ||
| 2023 | Late Stage Venture | 175.0M |
Investors
Avalyn Pharma is funded by 35 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| SR One | - | FUNDING ROUND - SR One | 175.0M |
| F-Prime Capital | - | FUNDING ROUND - F-Prime Capital | 175.0M |
| Avalyn Pharma | - | FUNDING ROUND - Avalyn Pharma | 175.0M |
| Novo Holdings | - | FUNDING ROUND - Novo Holdings | 175.0M |
Recent Activity
There is no recent news or activity for this profile.